Clinical Trials Directory

Trials / Completed

CompletedNCT04267029

Transfusion Associated Dyspnea Profiling

Transfusion-Associated Dyspnea: Prospective Observational and Laboratory Assessment

Status
Completed
Phase
Study type
Observational
Enrollment
151 (actual)
Sponsor
Toronto Transfusion Medicine Collaborative · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Transfusion reactions are defined as harms occurring during or after blood transfusion, with new heart/lung stress (eg. troubled breathing) regarded as cardiorespiratory transfusion reactions (CRTRs). CRTRs are among the most important, as the leading cause of transfusion-related harm and death. Though there are distinct classifications for these events, real life cases often don't fall neatly into a given category, with outliers regarded as "transfusion associated dyspnea (TAD)". It is unknown what TAD is -- whether it has a unique root cause, is a milder version of other known CRTRs, or is a blend of events. The purpose of this study is to better understand TAD and CRTRs by profiling them through a detailed medical history and more intensive laboratory assessment. This review of CRTRs may improve the quality/validity of final conclusions reported in the health record and to hemovigilance bodies, and uncover the nature of TAD and/or minimize CRTRs defaulting to the TAD category. Our enhanced understanding will advance diagnostic, treatment, and prevention efforts.

Detailed description

"Transfusion-Associated Dyspnea: Prospective Observation and Laboratory Assessment" (TADPOL) aims to improve the diagnosis and characterization of cardiorespiratory transfusion reaction (CRTR) patients ("cases"), as compared with high risk febrile transfusion reaction (HRFTR) patients ("controls"), by applying a standardized and intensive clinicolaboratory profiling tool. CRTR, in contrast with HRFTR, are more difficult to diagnose and manage. Patients are often sick with (or prone to) pathologies that resemble reactions (eg. congestive heart failure \[CHF\] vs transfusion associated circulatory overload \[TACO\]), and/or experience more than one transfusion-associated disturbance at a time. CRTRs are also the most disruptive, distressing, and disposition-escalating events for patients at an individual level, and are disproportionately accountable for transfusion associated deaths at the collective level in national hemovigilance systems. The cardinal CRTRs range from TACO (most commonly) to allergic bronchospasm to transfusion related acute lung injury (TRALI). Inaccurate classification may undercount certain phenomena (when criteria fail to be met by confounding conditions), and/or overcount others (when including all possibilities-of-relevance in hemovigilance). These uncertainties beget gaps (or excesses) in patient care and in donor/product-associated decision-making. HYPOTHESES: The TADPOL CRF and laboratory profiling effort will improve the yields of confident (more certain), accurate (better-grounded), and thorough (multi-event-sensitive) diagnoses in CRTR patients. Most cases of TAD are likely to be re-classified as milder versions (or overlaps) of possible CRTR states (± the underlying condition), while the remainder may exhibit a signature resembling FNHTR (FTR controls). Precise case-mapping should yield useful personalized information, while aggregated findings from each disturbance pathway - as they are distributed in each conventional reaction category - can validate the utility of markers being explored in reaction investigation algorithms. The TADPOL bioarchive and anonymized dataset will also be assets for explorations of novel indicators and patterns.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTTADPOL battery (deep clinicolaboratory profile)profile dimensions: * hemolytic * allergic * cardiorenal * inflammatory * leukoagglutinating * exploratory bioarchive

Timeline

Start date
2019-01-01
Primary completion
2022-10-04
Completion
2022-12-22
First posted
2020-02-12
Last updated
2023-05-03

Locations

4 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT04267029. Inclusion in this directory is not an endorsement.